Samsung Biologics is going to start its CRDMO strategy that covers consignment development (CDO) and.. – 매일경제

Language
Change font
A
A
A
A
Share
TOP
Most read
Language
Change font
A
A
A
A
Share
Samsung Biologics is going to start its CRDMO strategy that covers consignment development (CDO) and consignment research (CRO) based on global top tier consignment production (CMO) competitiveness. In the 8 years since the launch of the CDO business, it has secured 164 cumulative orders, while its customer base is rapidly shifting from domestic to global.
Samsung Biologics CDO Development Manager Lee Sang-myung held a meeting at the JPMorgan Healthcare Conference in San Francisco on the 15th (local time) and explained, “Since the launch of the consignment development (CDO) project in 2018, we have signed a total of 164 contracts and secured 49 clinical trial plan (IND) approval.” “In the beginning, the proportion of domestic customers was around 75%, but recently, the proportion of global customers has increased to 70-80%.”
CDO is a concept that encompasses all process development and production services necessary for entering clinical trials of new drug candidates. It covers not only cell lines, processes, analysis methods, and formulation development, but also production and supply of preclinical and clinical substances and IND approval support. Samsung Biologics has a total of nine technology platforms as of now, starting with the launch of its own cell line platform “SChoice” in August 2020.
The representative platform, S-Choice, has been advanced to the second generation. Through the development of new vectors and mother cells, antibody productivity has been increased from 7g/L to up to 13g/L. The speed of development has also been shortened compared to industry standards. Single antibodies can be produced in 11 months → 9 months, double antibodies 13 months → 11 months, and antibody drug conjugate (ADC) can be produced in 14.5 months through complex development with antibodies.
This year, it plans to internalize Master Cell Bank (MCB) and vector design services and introduce a new transferase-based platform. The company believes that this will further shorten the development timeline and strengthen the protection of intellectual property rights (IP) of customers.
Samsung Biologics introduced the patient-derived organoid-based CRO service “Samsung Organoid” in June last year, expanding its business area beyond CDO to the initial stage of finding candidate materials. By linking organoids with artificial intelligence (AI)-based development possibility evaluation platform ‘Developpick’, it plans to secure customers from the initial stage and promote an ‘early lock-in’ strategy that leads to CMO.
The CDO portfolio is rapidly advancing. Among the cumulative projects, high-value-added complex modalities such as double antibodies (20%), ADC (15%), and fusion proteins (14%) account for about half. “CDO is the first area to see what technologies and what substances will be produced by CMO in the future,” said Lee, “and it is important in that we can prepare technologies and products to be produced by CMO in advance in the next five to seven years.”
Samsung Biologics presented ‘technology-oriented leadership’ as a keyword for its CDO strategy in 2026. It plans to strengthen global technology leadership with data-oriented CDOs that combine AI, automation, and data, with three major pillars: securing initial partnerships, data-based operations, and creating high added value.
“CDO is a key business that is directly connected to the success of customers’ new drug development rather than the size of sales,” Lee said. “We will establish ourselves as a full-time partner in global new drug development through a one-stop CRDMO model that naturally connects CMO.”
2026-01-17 17:13:03
2026-01-19 10:48:19
2026-01-18 16:49:48
2026-01-18 09:30:14
2026-01-19 07:51:18
2026-01-19 06:14:35
2026-01-19 10:07:46
2026-01-19 11:08:07
2026-01-19 11:05:26
2026-01-19 11:15:57
※ This article was translated using AI technology for reader convenience.
Maeil Business Newpaper(MK) provides these translations “as they are” and makes no warranties of any kind, either explicitly or implicitly, regarding accuracy, reliability and marketability, suitability for a particular purpose, etc. of translation. Please be informed that the content provided may not be translated accurately due to limitations in machine translation before using this service.
Copyright (c) 매경AX. Maeil Business News Korea & mk.co.kr, All rights reserved.
Prohibition of unauthorized reproduction, redistribution, and use of AI learning

source